The antibody discovery market was valued at $6.9 billion in 2022, and is estimated to reach $17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032.Antibody discovery is defined as a process of identifying novel therapeutic antibodies to treat a wide range of diseases such as autoimmune diseases, cancer, human immunodeficiency virus, and hereditary diseases. The antibody discovery process is different from the traditional discovery of small molecules, as it requires the engineering of antibodies and development of hybridomas to recognize a specific target protein. The antibody discovery includes various steps such as target assessment, followed by hit generation and lead optimization, through a variety of molecular engineering and synthetic biology methods.
The antibody discovery market is driven by the increase in demand for antibody in various R&D activities and advancement in technology in the antibody discovery process. Antibody is one of the most commonly used candidate for development of drugs. It is used to detect, isolate, and quantify proteins, as well as to identify and study the molecular and cellular pathways that are involved in a variety of diseases. They are also used to develop vaccines, therapeutics, and diagnostic tests. In addition, antibodies are used in research centers to study the structure and function of proteins, drug development, and other biomedical applications. For instance, in November 2022, Ablexis, LLC, a biopharmaceutical company, announced the licensing of AlivaMab mouse technology for antibody drug discovery. The technology increases the process of antibody drug engineering. The novel strain of AlivaMab XKL mice aims to enhance the epitope and molecular diversity of immune response during antibody drug discovery.
The increase in adoption of key strategies such as product launch and product expansion drive the growth of the market. For instance, in November 2022, Ablexis, LLC and AlivaMab Discovery Services, announced the expansion of platform for antibody drug discovery and engineering process. Moreover, in December 2021, OpenEye Scientific and Specifica, Inc, announced the launch of orion antibody discovery suite. It is a next generation sequencing software, which helps bioinformaticians and antibody manufacturing engineer at biotechnology and pharmaceutical companies to advance antibody discovery by identifying a wide range of antibody set with advanced properties for downstream therapeutic development. Thus, increase in product launch propels the growth of the market.
In addition, rise in prevalence of cancer & other chronic diseases, surge in adoption of antibody in the treatment of several diseases including inflammatory, cancer, & autoimmune diseases, and increase in investment in R&D activities in pharmaceutical and biotechnology industry propel the growth of the market. The most common approach for antibody discovery is the use of phage display method. In addition, antibodies can be used to detect the presence of cancer cells in the body, aiding in the early diagnosis of the disease. For instance, in December 2021, BioGenex, an automated staining provider for cancer diagnosis, announced the launch of three novel antibody for diagnosis of cancer. According to the Worldwide Cancer Data, in 2020, around 18.1 million people across the globe were diagnosed with cancer. Thus, the increase in demand for antibody in diagnosis of cancer foster the need for antibody development.
In addition, increase in geriatric population fosters the demand for therapeutic antibody, which drives the growth of the antibody market. Geriatric population is more prone to chronic diseases that augments the need for customized and tailored antibody, which boost the demand for antibody discovery services. Furthermore, the increase in need for antibody discovery for the development of novel therapeutics and vaccine boost the growth of the market.
Moreover, rise in prevalence of neurogenerative diseases, such as alzheimer, parkinsons, and huntington, boost the growth of the antibody discovery market. Furthermore, rise in number of government fundings for R&D activities further boost the market growth. For instance, in March 2023, Antiverse Ltd, a biotechnology company, announced that it has raised $3 million in funding, to enable in-house development of the antibodies.
However, a factor that hinders the market growth is high cost of antibody discovery process. On the other hand, increase in the number of R&D activities for novel antibody manufacturing and increase in number of key players who provide antibody discovery services are expected to create immense opportunities for antibody discovery market during the forecast period.
The antibody discovery market is segmented on the basis of method, antibody type, end user, and region. On the basis of method, the market is classified into phage display, hybridoma, and others. On the basis of antibody type, the market is categorized into humanized antibody, human antibody, chimeric antibody, and murine antibody.
On the basis of end user, the market is fragmented into pharmaceutical & biotechnology industry, research laboratory, and academic laboratory.
Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antibody discovery market are Genscript Technology, Danaher Corporation, Twist Bioscience HQ, Sartorius AG, Charles River Laboratories, Eurofins Discovery, Fairjourney Biologics SA, Biocytogen, Creative Biolab, and Evotec. Key players operating in the market have adopted product launch and others as their key strategies to expand their market share.
The antibody discovery market is driven by the increase in demand for antibody in various R&D activities and advancement in technology in the antibody discovery process. Antibody is one of the most commonly used candidate for development of drugs. It is used to detect, isolate, and quantify proteins, as well as to identify and study the molecular and cellular pathways that are involved in a variety of diseases. They are also used to develop vaccines, therapeutics, and diagnostic tests. In addition, antibodies are used in research centers to study the structure and function of proteins, drug development, and other biomedical applications. For instance, in November 2022, Ablexis, LLC, a biopharmaceutical company, announced the licensing of AlivaMab mouse technology for antibody drug discovery. The technology increases the process of antibody drug engineering. The novel strain of AlivaMab XKL mice aims to enhance the epitope and molecular diversity of immune response during antibody drug discovery.
The increase in adoption of key strategies such as product launch and product expansion drive the growth of the market. For instance, in November 2022, Ablexis, LLC and AlivaMab Discovery Services, announced the expansion of platform for antibody drug discovery and engineering process. Moreover, in December 2021, OpenEye Scientific and Specifica, Inc, announced the launch of orion antibody discovery suite. It is a next generation sequencing software, which helps bioinformaticians and antibody manufacturing engineer at biotechnology and pharmaceutical companies to advance antibody discovery by identifying a wide range of antibody set with advanced properties for downstream therapeutic development. Thus, increase in product launch propels the growth of the market.
In addition, rise in prevalence of cancer & other chronic diseases, surge in adoption of antibody in the treatment of several diseases including inflammatory, cancer, & autoimmune diseases, and increase in investment in R&D activities in pharmaceutical and biotechnology industry propel the growth of the market. The most common approach for antibody discovery is the use of phage display method. In addition, antibodies can be used to detect the presence of cancer cells in the body, aiding in the early diagnosis of the disease. For instance, in December 2021, BioGenex, an automated staining provider for cancer diagnosis, announced the launch of three novel antibody for diagnosis of cancer. According to the Worldwide Cancer Data, in 2020, around 18.1 million people across the globe were diagnosed with cancer. Thus, the increase in demand for antibody in diagnosis of cancer foster the need for antibody development.
In addition, increase in geriatric population fosters the demand for therapeutic antibody, which drives the growth of the antibody market. Geriatric population is more prone to chronic diseases that augments the need for customized and tailored antibody, which boost the demand for antibody discovery services. Furthermore, the increase in need for antibody discovery for the development of novel therapeutics and vaccine boost the growth of the market.
Moreover, rise in prevalence of neurogenerative diseases, such as alzheimer, parkinsons, and huntington, boost the growth of the antibody discovery market. Furthermore, rise in number of government fundings for R&D activities further boost the market growth. For instance, in March 2023, Antiverse Ltd, a biotechnology company, announced that it has raised $3 million in funding, to enable in-house development of the antibodies.
However, a factor that hinders the market growth is high cost of antibody discovery process. On the other hand, increase in the number of R&D activities for novel antibody manufacturing and increase in number of key players who provide antibody discovery services are expected to create immense opportunities for antibody discovery market during the forecast period.
The antibody discovery market is segmented on the basis of method, antibody type, end user, and region. On the basis of method, the market is classified into phage display, hybridoma, and others. On the basis of antibody type, the market is categorized into humanized antibody, human antibody, chimeric antibody, and murine antibody.
On the basis of end user, the market is fragmented into pharmaceutical & biotechnology industry, research laboratory, and academic laboratory.
Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antibody discovery market are Genscript Technology, Danaher Corporation, Twist Bioscience HQ, Sartorius AG, Charles River Laboratories, Eurofins Discovery, Fairjourney Biologics SA, Biocytogen, Creative Biolab, and Evotec. Key players operating in the market have adopted product launch and others as their key strategies to expand their market share.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody discovery market analysis from 2022 to 2032 to identify the prevailing antibody discovery market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antibody discovery market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antibody discovery market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Methods
- Phage Display
- Hybridoma
- Others
By Antibody Type
- Humanized Antibody
- Human Antibody
- Chimeric Antibody
- Murine Antibody
By End Users
- Pharmaceutical and Biotechnology industry
- Research laboratory
- Academic laboratory
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Biocytogen
- Charles River Laboratories
- Creative Biolabs
- Danaher Corporation
- Eurofins Scientific
- Evotec
- Fairjourney Biologics S.A
- Genscript Technology Corporation
- Sartorius AG
- Twist Bioscience
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTIBODY DISCOVERY MARKET, BY METHODS
CHAPTER 5: ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE
CHAPTER 6: ANTIBODY DISCOVERY MARKET, BY END USERS
CHAPTER 7: ANTIBODY DISCOVERY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Biocytogen
- Charles River Laboratories
- Creative Biolabs
- Danaher Corporation
- Eurofins Scientific
- Evotec
- Fairjourney Biologics S.A
- Genscript Technology Corporation
- Sartorius AG
- Twist Bioscience
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
